Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
14
×
boston blog main
14
×
deals
14
×
life sciences
national blog main
boston top stories
clinical trials
national top stories
boston
san francisco blog main
fda
san francisco top stories
startups
alnylam pharmaceuticals
investing
new york blog main
new york top stories
sanofi
alexion pharmaceuticals
hepatitis b
ipo
rna interference
roche
abbvie
akouos
allergan
amgen
autoimmune disorders
boehringer ingelheim
cancer
crispr
editas medicine
eli lilly
genentech
glaxosmithkline
indiana blog main
indiana top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
What
medicines
14
×
drug
deal
new
disease
research
biotech
fda
ipo
pharma
therapeutics
adds
ago
alliance
called
cancer
candidate
company
developing
dicerna
gene
hepatitis
pact
pharmaceuticals
plans
potential
roche
startup
targets
team
years
abandoning
abbvie
acquire
acquisitions
address
affects
agreed
aiming
aims
Language
unset
Current search:
biotech
×
deals
×
" boston blog main "
×
medicines
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?